Metabolic Fingerprint of Acromegaly and Its Potential Usefulness in Clinical Practice
Biagetti, Betina (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Herance, José Raul (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Ferrer Costa, Roser (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Aulinas, Anna (Hospital Universitari de Vic)
Palomino-Schätzlein, Martina (Centro de Investigación Príncipe Felipe (València))
Mesa Manteca, Jordi (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Castaño, Justo P.. (Department of Cell Biology, Physiology, and Immunology, CIBERobn, 14004 Cordoba, Spain)
Luque, Raul M. (CIBERobn (Córdoba))
Simó Canonge, Rafael (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Universitat Autònoma de Barcelona

Fecha:	2019
Resumen:	Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels are the main targets for monitoring acromegaly activity, but they are not in close relationship with the clinical course of the disease and the associated comorbidities. The present study was aimed at identifying metabolites that could be used as biomarkers for a better disease phenotyping. For this purpose, metabolic fingerprint using an untargeted metabolomic approach was examined in serum from 30 patients with acromegaly and 30 age-matched controls. Patients with acromegaly presented fewer branched-chain amino acids (BCAAs) compared to the control group (valine: 4. 75 ± 0. 87 vs. 5. 20 ± 1. 06 arbitrary units (AUs), p < 0. 05; isoleucine: 2. 54 ± 0. 41 vs. 2. 80 ± 0. 51 AUs; p < 0. 05). BCAAs were also lower in patients with active disease compared to patients with normal levels of IGF-1 with or without medical treatment. GH, but not IGF-1, serum levels were inversely correlated with both valine and isoleucine. These findings indicate that low levels of BCAAs represent the main metabolic fingerprint of acromegaly and that GH, rather than IGF-1, might be the primary mediator. In addition, our results suggest that the assessment of BCAAs could help to identify active disease and to monitor the response to therapeutic strategies.
Ayudas:	Ministerio de Ciencia e Innovación BFU2016-80360-R Ministerio de Economía y Competitividad PI16/00264 Ministerio de Economía y Competitividad CP15/00156
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Acromegaly ; Metabolomics ; Amino acids ; Branched chain ; Insulin resistance ; Muscular weakness
Publicado en:	Journal of clinical medicine, Vol. 8 (september 2019) , ISSN 2077-0383

DOI: 10.3390/jcm8101549
PMID: 31561638

14 p, 1.4 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados